Last reviewed · How we verify
TEGAFUR URACIL - FOLINIC ACID
TEGAFUR URACIL - FOLINIC ACID is a Antimetabolite Small molecule drug developed by Centre Oscar Lambret. It is currently in Phase 3 development for Advanced colorectal cancer, Gastric cancer.
Tegafur uracil combined with folinic acid enhances the cytotoxic effects of 5-fluorouracil by increasing its intracellular concentration and prolonging its action.
Tegafur uracil combined with folinic acid enhances the cytotoxic effects of 5-fluorouracil by increasing its intracellular concentration and prolonging its action. Used for Advanced colorectal cancer, Gastric cancer.
At a glance
| Generic name | TEGAFUR URACIL - FOLINIC ACID |
|---|---|
| Sponsor | Centre Oscar Lambret |
| Drug class | Antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tegafur is converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and disrupts DNA synthesis. Folinic acid potentiates the effect of 5-FU by enhancing its conversion to its active metabolites and reducing its degradation.
Approved indications
- Advanced colorectal cancer
- Gastric cancer
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer (PHASE3)
- Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (PHASE3)
- Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (PHASE2)
- Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment (PHASE2, PHASE3)
- HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer (PHASE2)
- Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer (PHASE2)
- Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEGAFUR URACIL - FOLINIC ACID CI brief — competitive landscape report
- TEGAFUR URACIL - FOLINIC ACID updates RSS · CI watch RSS
- Centre Oscar Lambret portfolio CI
Frequently asked questions about TEGAFUR URACIL - FOLINIC ACID
What is TEGAFUR URACIL - FOLINIC ACID?
How does TEGAFUR URACIL - FOLINIC ACID work?
What is TEGAFUR URACIL - FOLINIC ACID used for?
Who makes TEGAFUR URACIL - FOLINIC ACID?
What drug class is TEGAFUR URACIL - FOLINIC ACID in?
What development phase is TEGAFUR URACIL - FOLINIC ACID in?
What are the side effects of TEGAFUR URACIL - FOLINIC ACID?
What does TEGAFUR URACIL - FOLINIC ACID target?
Related
- Drug class: All Antimetabolite drugs
- Target: All drugs targeting Thymidylate synthase
- Manufacturer: Centre Oscar Lambret — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced colorectal cancer
- Indication: Drugs for Gastric cancer
- Compare: TEGAFUR URACIL - FOLINIC ACID vs similar drugs
- Pricing: TEGAFUR URACIL - FOLINIC ACID cost, discount & access